Hepatitis D: not a rare disease anymore: global update for 2017–2018

Shen, Dan‐Ting; Ji, Dong‐Ze; Chen, Haiyan; Goyal, Hemant; Pan, Shiyang; Xu, Hua‐Guo

doi:10.1136/gutjnl-2019-318691

Cited by 24 publications

(28 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Global estimates for HDV range from 48 to 74 million people. [34][35][36][37][38] High prevalence areas include Central and West Africa, Central Asia, Mongolia, Pakistan, some Pacific Islands, Eastern Europe, the Middle East and Turkey, the Amazonian basin, and Greenland. China accumulates the largest number of HDVinfected people, Pakistan being second.…”

Section: Hepatitis Deltamentioning

confidence: 99%

Advances in hepatitis B therapeutics

Soriano¹,

Barreiro

Kottilil

et al. 2020

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of hepatocellular carcinoma, which represents the third cause of cancer mortality, accounting for nearly 1 million annual deaths. Current oral nucleos(t)ide therapy with tenofovir or entecavir suppresses serum HBV-DNA in most treated patients, but rarely is accompanied by HBsAg loss. Thus, treatment has to be given lifelong to prevent viral rebound. A broad spectrum of antivirals that block the HBV life cycle at different steps are in clinical development, including entry inhibitors, cccDNA disrupters/silencers, translation inhibitors, capsid assembly modulators, polymerase inhibitors and secretion inhibitors. Some of them exhibit higher potency than current oral nucleos(t)ides. Drugs in more advanced stages of clinical development are bulevirtide, JNJ-6379, ABI-H0731, ARO-HBV and REP-2139. To date, only treatment with ARO-HBV and with REP-2139 have resulted in HBsAg loss in a significant proportion of patients. Combination therapies using distinct antivirals and/or immune modulators are expected to maximize treatment benefits. The current goal is to achieve a ‘functional cure’, with sustained serum HBsAg after drug discontinuation. Ultimately, the goal of HBV therapy will be virus eradication, an achievement that would require the elimination of the cccDNA reservoir within infected hepatocytes.

show abstract

Section: Hepatitis Deltamentioning

confidence: 99%

Advances in hepatitis B therapeutics

Soriano¹,

Barreiro

Kottilil

et al. 2020

Therapeutic Advances in Infection

View full text Add to dashboard Cite

show abstract

“…Although this has been estimated to lie around 5% of the worldwide population infected with HBV (ie ~13 million out of the estimated 257 million HBV carriers), recent work points at much higher figures, that is, up to 72 million persons infected . The methodology and conclusions of this study were seriously questioned, but a reappraisal of the initial meta‐analysis confirmed, nonetheless, the gross underestimation of the worldwide HDV prevalence, emphasizing, in addition, the lack of good quality data. Most prevalence studies have been conducted in low‐risk populations, blood donors and limited geographical areas, which make it impossible to extrapolate their conclusions to whole countries.…”

mentioning

confidence: 76%

The heavy burden of hepatitis D in Uzbekistan

Negro

2019

Liver International

View full text Add to dashboard Cite

show abstract

“…1 To better estimate HDV burden, we revisited the previous studies on this topic (Table 1). [1][2][3][4][5][6][7][8][9] We re-estimated HDV prevalence using 2 approaches based on the general population or HBV carriers, respectively. Among the general population, we calculated the overlap interval of the lower bound of these previous metaanalyses, but excluded the current Stockdale study due to their bias.…”

Section: Revisiting the Estimation Of Hepatitis D Global Prevalencementioning

confidence: 99%

“…As described, 2 we excluded HDV IgM antibody and HDV antigen as these markers are inconsistently expressed in people with HDV infection. 5 Although some previous meta-analyses included markers such as HDV IgM and HDV antigen, we…”

Section: Reply To: "Revisiting the Estimation Of Hepatitis D Global Pmentioning

confidence: 99%